Skip to main content

Advertisement

Table 3 Characteristics in the One Subject With Treatment-Emergent Tardive Dyskinesia as Per Defined Research Criteria

From: Evaluating movement disorders in pediatric patients receiving risperidone: a comparison of spontaneous reports and research criteria for TD

Gender Male
Age 10 y
Diagnosis Oppositional defiant disorder
Intellligence quotient (IQ) 59
NCBRF total score   
   Baseline 33
   Endpoint 31
Time point Risperidone dose (mg/day) Dyskinesia score*
   Baseline 0.000 3
   Week 1 0.343 3
   Week 2 1.200 3
   Week 3 1.814 3
   Week 4 1.900 3
   Week 8 1.784 ---
   Week 12 1.300 4
   Week 16 1.300 7
   Week 20 1.300 7
   Week 24 1.300 1
   Week 36 1.300 2
   Week 48 1.300 0
  1. NCBRF indicates Nisonger Child Behavior Rating Form.
  2. *Extrapyramidal Symptom Rating Scale (ESRS) physician's examination for dyskinesia, items E51–57.